Comparative Pharmacology
Head-to-head clinical analysis: EQUANIL versus PLACIDYL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EQUANIL versus PLACIDYL.
EQUANIL vs PLACIDYL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Gamma-aminobutyric acid (GABA) receptor positive allosteric modulator; increases frequency of chloride channel opening, potentiating inhibitory neurotransmission.
Ethchlorvynol is a sedative-hypnotic that depresses the central nervous system at the level of the brainstem and reticular formation, potentiating GABAergic inhibition. Its exact molecular mechanism is not fully defined.
400 mg orally 3-4 times daily; maximum 2400 mg/day. Alternatively, 200 mg orally 3-4 times daily for mild anxiety.
500 mg to 1000 mg orally at bedtime, as a hypnotic. Usual dose is 500 mg to 750 mg. Maximum dose 1000 mg.
None Documented
None Documented
Terminal elimination half-life is 6-20 hours (mean 10 hours). In hepatic cirrhosis, half-life may be prolonged to 24-36 hours due to impaired clearance.
Terminal elimination half-life is approximately 24 hours (range 10-40 hours), with prolonged elimination in hepatic impairment and overdose due to saturation of metabolism.
Primarily renal excretion of conjugated metabolites (inactive); approximately 90% of a dose is excreted in urine, with less than 10% in feces. Less than 5% is excreted unchanged.
Primarily renal excretion of metabolites; less than 1% excreted unchanged. Biliary/fecal elimination accounts for 30-40% of metabolites, with enterohepatic recycling.
Category C
Category C
Sedative-Hypnotic
Sedative-Hypnotic